VA launches trial to test GLP-1 medication for alcohol use disorder in veterans
The Department of Veterans Affairs has initiated a nationwide clinical trial to determine if semaglutide can effectively treat alcohol use disorder among veterans. This medication, widely recognized by brand names like Ozempic and Wegovy, is currently approved for managing Type 2 diabetes and chronic weight issues. Researchers now aim to verify if its impact on brain reward systems offers a viable path for veterans struggling with alcohol dependency.
The study, titled the Cessation or Reduction of Alcohol Consumption in Veterans trial, will include over 600 participants between the ages of 18 and 80. These individuals will be drawn from 18 separate medical centers across the United States. Throughout the 24-week program, veterans will receive either weekly injections of the medication or a placebo to measure changes in consumption patterns and overall health.
VA officials stress that this medication is not yet an approved treatment for alcohol use disorder. They caution veterans against attempting to use these drugs without direct medical supervision or replacing existing evidence-based care plans with experimental options. The agency intends to use the collected data to decide whether this drug provides a safe, standard clinical solution for the 400,000 veterans currently diagnosed with this condition.
This trial follows earlier observations that patients taking GLP-1 medications for other health needs reported a decrease in substance use. The VA is actively recruiting for this study as of late July 2026. Veterans interested in the research are directed to contact their local medical center or check the federal database for additional enrollment details.